MSFT   157.73 (-0.28%)
AMZN   1,836.32 (-2.55%)
CGC   18.06 (-2.06%)
NVDA   258.31 (+2.26%)
BABA   202.25 (-1.36%)
MU   51.05 (+0.93%)
GE   10.35 (-0.39%)
TSLA   640.62 (-5.65%)
F   6.81 (-2.44%)
NFLX   357.29 (-3.88%)
BAC   27.86 (-4.36%)
MSFT   157.73 (-0.28%)
AMZN   1,836.32 (-2.55%)
CGC   18.06 (-2.06%)
NVDA   258.31 (+2.26%)
BABA   202.25 (-1.36%)
MU   51.05 (+0.93%)
GE   10.35 (-0.39%)
TSLA   640.62 (-5.65%)
F   6.81 (-2.44%)
NFLX   357.29 (-3.88%)
BAC   27.86 (-4.36%)
MSFT   157.73 (-0.28%)
AMZN   1,836.32 (-2.55%)
CGC   18.06 (-2.06%)
NVDA   258.31 (+2.26%)
BABA   202.25 (-1.36%)
MU   51.05 (+0.93%)
GE   10.35 (-0.39%)
TSLA   640.62 (-5.65%)
F   6.81 (-2.44%)
NFLX   357.29 (-3.88%)
BAC   27.86 (-4.36%)
MSFT   157.73 (-0.28%)
AMZN   1,836.32 (-2.55%)
CGC   18.06 (-2.06%)
NVDA   258.31 (+2.26%)
BABA   202.25 (-1.36%)
MU   51.05 (+0.93%)
GE   10.35 (-0.39%)
TSLA   640.62 (-5.65%)
F   6.81 (-2.44%)
NFLX   357.29 (-3.88%)
BAC   27.86 (-4.36%)
Log in

NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News

$3.02
+0.02 (+0.67 %)
(As of 02/28/2020 02:20 PM ET)
Today's Range
$2.85
Now: $3.02
$3.07
50-Day Range
$3.00
MA: $3.85
$4.54
52-Week Range
$2.60
Now: $3.02
$5.13
Volume1.46 million shs
Average Volume1.17 million shs
Market Capitalization$492.14 million
P/E Ratio301.80
Dividend YieldN/A
Beta0.92
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.55 million
Book Value$0.25 per share

Profitability

Net Income$-6,510,000.00

Miscellaneous

Employees165
Market Cap$492.14 million
Next Earnings Date3/3/2020 (Confirmed)
OptionableOptionable

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.


Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) announced its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The specialty pharmaceutical company earned $34.31 million during the quarter, compared to analysts' expectations of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. View Antares Pharma's Earnings History.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Antares Pharma.

How can I listen to Antares Pharma's earnings call?

Antares Pharma will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $149.16 million.

What price target have analysts set for ATRS?

2 equities research analysts have issued 12 month price targets for Antares Pharma's stock. Their forecasts range from $5.00 to $5.65. On average, they anticipate Antares Pharma's stock price to reach $5.33 in the next year. This suggests a possible upside of 77.5% from the stock's current price. View Analyst Price Targets for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

Media stories about ATRS stock have trended very negative on Friday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -3.0 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Antares Pharma.

Are investors shorting Antares Pharma?

Antares Pharma saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 5,540,000 shares, an increase of 17.6% from the January 30th total of 4,710,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the days-to-cover ratio is currently 3.0 days. Approximately 3.7% of the shares of the company are short sold. View Antares Pharma's Current Options Chain.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Conatus Pharmaceuticals (CNAT), Novavax (NVAX), NVIDIA (NVDA), Prospect Capital (PSEC), Advanced Micro Devices (AMD), Hi-Crush Partners (HCLP), Macquarie Infrastructure (MIC), Canopy Growth (CGC) and AT&T (T).

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.51%), Sargent Investment Group LLC (2.51%), Sargent Investment Group LLC (2.30%), FMR LLC (1.98%), Geode Capital Management LLC (1.30%) and Renaissance Technologies LLC (0.70%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Healthcare Value Capital LLC, Bank of America Corp DE, Perkins Capital Management Inc., Principal Financial Group Inc., New York State Common Retirement Fund, Bernardo Wealth Planning LLC and PNC Financial Services Group Inc.. Company insiders that have sold Antares Pharma company stock in the last year include Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sargent Investment Group LLC, Goldman Sachs Group Inc., EAM Investors LLC, EAM Global Investors LLC, Sargent Investment Group LLC, Oracle Investment Management Inc. and Marshall Wace LLP. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $3.00.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $489.69 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

What is Antares Pharma's official website?

The official website for Antares Pharma is http://www.antarespharma.com/.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected].com.


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  670
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel